Patent · US Active

Direct AMPK activators

US11174246B2 · kind B2 · utility

0Cited by

1References

33Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Simon Shaw · Oakland, US
Xiang Xu · San Francisco, US
Sarkiz Issakani · San Jose, US
Rajinder Singh · Belmont, US
Yasumichi Hitoshi · Brisbane, US
Matthew Duncton · San Bruno, US
Nan Lin · Tainan, TW

Key dates

Filing date	Aug 15, 2017
Grant date	Nov 16, 2021
Priority date	—
Expiry date	Aug 15, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D403/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, R2, R3, R4, Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.